Oral bisphosphonate, alendronate, for the treatment of acute Charcot neuroarthropathy in diabetic patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN86625608

Enrollment

Registered

2010-07-30

Start date

2008-02-01

Completion date

Unknown

Last updated

2017-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Topic: Diabetes Research Network

Interventions

Alendronate Follow-up length: 12 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Type 1 or type 2 diabetes 2. Aged 18 - 85 years 3. Diabetic neuropathy 4. Active Charcot arthropathy

Exclusion criteria

Exclusion criteria: 1. Peripheral vascular disease 2. Renal failure 3. Foot ulceration or celluitis or osteomyelitis 4. Previous amputation (more than midfoot) 5. Contraindication to study drug 6. Oesophageal or gastric problems (achalasia, ulcers) 7. Pregnancy 8. Breastfeeding 9. Risk factors for jaw osteonecrosis

Design outcomes

Primary

Measure	Time frame
Reduction in Charcot disease activity	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026